Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73344
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73344
Character Range: 16293–17246

73344              Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non‑small cell lung cancer, which is of non‑squamous histology or histology not otherwise specified, with documented evidence of ROS proto‑oncogene 1 (ROS1) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+; and with documented absence of both activating mutations of the epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) immunoreactivity by IHC, requested by a specialist or consultant physician, if the test is:   400.00
                     (a) to determine if requirements relating to ROS1 gene arrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled: and
                     (b) not associated with a service to which item 73437 or 73439 applies